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ABSTRACT Estradiol acts rapidly and directly to inhibit L-type Ca2þ current in
medium spiny neurons from striatum. Since medium spiny neurons contain g-amino-
butyric acid (GABA), we hypothesized that estradiol inhibition of Ca2þ channel cur-
rent in the cell body would result in decreased GABA release. In this study, we exam-
ined the effect of estradiol on the concentration of GABA, taurine, and glutamate in
dialysate from striatum. In support of our hypothesis, the K+-evoked increase in
GABA, but not taurine or glutamate, was significantly attenuated 30 min after treat-
ment with estradiol. Synapse 59: 122–124, 2006. VC 2005 Wiley-Liss, Inc.
INTRODUCTION
g-Aminobutyric acid (GABA) is an inhibitory neuro-
transmitter and estradiol inhibits GABA activity in the
cerebellum, hippocampus, and hypothalamus (Ledoux
and Woolley, 2005; Malyala et al., 2005; Smith et al.,
2000). In addition, in whole-cell clamp recordings from
acutely dissociated striatal neurons, estradiol rapidly
induces a decrease in current flow through L-type Ca2þ
channels on cell bodies of medium spiny neurons that
are presumably GABAergic (Mermelstein et al., 1996).
This occurs within seconds by acting at the external
membrane surface to alter G-protein coupled signaling
pathways (Mermelstein et al., 1996). Inhibition of Ca2þ
current mediated by L-type Ca2þ channels on cell
bodies decreases neurotransmitter release from neu-
rons (Vigh and Lasater, 2004). We therefore hypothe-
sized that estradiol would inhibit stimulated GABA
release in striatum via inhibition of L-type Ca2þ chan-
nels at the cell body. As an initial test of this hypothe-
sis, the present study was conducted to investigate the
effect of acute estradiol administration on concentra-
tions of GABA in dialysate from striatum. The effects
of estradiol on the extracellular concentrations of taur-
ine and glutamate were also examined.
Female Sprague-Dawley rats (200–225 g; Harlan,
Indianapolis, IN) were ovariectomized and underwent
in vivo microdialysis as previously described (Becker
and Rudick, 1999). Fifteen to eighteen hours after di-
alysis probe insertion into brain through a chronic guide
cannula, Ringer’s solution was perfused at 1 ll/min, and
on-line analysis of the dialysate was performed using
capillary electrophoresis with laser-induced fluorescence,
as described previously (Bowser and Kennedy, 2001;
Presti et al., 2004). After basal levels of amino acids
were established the rat received a subcutaneous injec-
tion of 5 lg estradiol benzoate (EB, n ¼ 6) in 0.1 ml of
peanut oil or 0.1 ml of peanut oil (vehicle, n ¼ 7). Thirty
minutes later additional electropherograms were col-
lected to determine the effect of EB on basal GABA
overflow. With the instrument continuously sampling
dialysate, a 10-min, 75 mM Kþ stimulation was initi-
ated by reverse dialysis. Electropherograms collected
during the 10-min stimulation, and 30-min poststimula-
tion period was used to determine effects of estradiol on
stimulated GABA release. Probe placement in the stria-
tum was confirmed by histological analysis.
Basal concentrations of GABA, taurine, and gluta-
mate varied from individual to individual, but did not
differ between the vehicle and EB groups, and were
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not significantly affected by treatment with EB or
vehicle. Local perfusion of 75 mM Kþ for 10 min pro-
duced a transient increase of GABA and taurine in
the extracellular fluid from both vehicle and EB-
treated rats (Fig. 1). The peak concentration of GABA
was observed 8 min after the initiation of Kþ stimula-
tion (Fig. 1A) and the peak concentration of taurine
was seen 15 min after initiation of Kþ stimulation
(Fig. 1B). Pretreatment with 5 lg of EB significantly
attenuated the Kþ-induced increase in extracellular
GABA concentration in dialysate compared with that
of the vehicle-treated OVX rats (Fig. 1A). Pretreat-
ment with 5 lg of EB, however, did not significantly
attenuate the Kþ-induced increase in extracellular
taurine concentration in dialysate compared with that
of vehicle-treated OVX rats. When results were ana-
lyzed by two way ANOVA with repeated measures,
there was a main effect of treatment (F1,11 ¼ 7.24,
P < 0.021), a treatment X time interaction (F11,54 ¼
3.020, P < 0.0001), and an effect of time of sample
collection (F1,54 ¼ 23.61, P < 0.0001) on increase in
GABA concentration. Posthoc pairwise comparisons
indicated that Kþ-stimulated increase in GABA was
greater for the vehicle-treated group than for the
group that received EB 30 min before stimulation.
On the other hand, for taurine concentrations in
dialysate there was no main effect of treatment (F1,10 ¼
0.869, P ¼ 0.37), but there was a treatment X time
interaction (F10,54 ¼ 2.94, P < 0.0001), and an effect of
time of sample collection (F1,54 ¼ 5.89, P < 0.0001).
Subsequent pairwise comparisons did not find any time
points where taurine concentrations from the EB-
treated rats differed significantly from the vehicle-
treated OVX rats, nor was there a difference when the
areas under the curve were compared.
Local perfusion of 75 mM Kþ for 10 min did not sig-
nificantly affect the glutamate concentration in dialy-
sate from either vehicle or EB-treated rats. For the
vehicle group, the concentration of glutamate was
26.6 6 4.87 pg/ll pre-Kþ and 17.8 6 3.4 pg/ll post-
Kþ, while for the estradiol-treated group the concen-
tration of glutamate was 26.2 6 5.51 pg/ll pre-Kþ
and 16.9 6 3.5 pg/ll post-Kþ.
In conclusion, our results indicate that estradiol
rapidly inhibits Kþ-stimulated increases in extracellu-
lar GABA in striatum, suggesting that estradiol
inhibits the release of GABA from neurons. When
estradiol binds to membrane-associated receptors for
estradiol, L-type Ca2þ channels are blocked, and so
the decreased Ca2þ is hypothesized to contribute to
this reduced GABA release. Alternatively, estradiol
may decrease the amount of GABA released by
changing the presynaptic distribution of GABA con-
taining vesicles as demonstrated in the hippocampus
by Ledoux and Woolley (2005).
The extracellular concentrations of GABA detected
using dialysis do not solely reflect exocytotic release of
GABA from synapses (Del Arco et al., 2003). Never-
theless, stimulated increases in GABA detected in
dialysate after methamphetamine or cocaine have been
shown to reflect alterations in neural activity and
function (Bustamante et al., 2002; Xi et al., 2003). Fur-
Fig. 1. Thirty minutes after injection of 5 lg of estradiol ben-
zoate (EB) or vehicle, 75 mM Kþ was introduced by reverse dialysis
for 10 min. A: Estradiol attenuates Kþ-induced GABA in dialysate
(mean 6 SEM). For EB, n ¼ 6; for vehicle, n ¼ 7. *EB significantly
inhibited Kþ-induced GABA detected in dialysate relative to vehicle-
treated control animals (P < 0.028). B: Estradiol does not attenuate
Kþ-induced taurine in dialysate (mean 6 SEM). For EB, n ¼ 6; for
vehicle, n ¼ 6 (taurine data from one animal was lost as the scale
was set wrong).
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thermore, Kþ-evoked increases in GABA are inhibited
if tetrodotoxin is included or if Ca2þ is excluded from
the dialysis Ringer’s (Campbell et al., 1993; Hondo
et al., 1995), supporting the hypothesis that such
increases are derived from neuronal activity.
In this study we found that there is no effect of
estradiol on the increase in taurine in dialysate fol-
lowing Kþ stimulation. Interestingly, the increase in
Kþ-stimulated taurine was delayed relative to the
period of stimulation and relative to the increase in
GABA. Such delays have been reported before (Ritz
et al., 2002). Although the exact mechanism of Kþ-
evoked taurine efflux is not known, its relatively slow
rise suggests its release may be secondary to other
changes, or nonneuronal in origin. We also did not
find an effect of estradiol on glutamate in dialysate
following Kþ stimulation. From these findings we con-
clude that the effect of estradiol on GABA is not
mediated by taurine or glutamate, and the results are
consistent with a direct effect on GABA neurons.
Previous research has demonstrated that estradiol
rapidly enhances stimulated dopamine (DA) release
in the striatum (Becker, 1999; Becker, 2000; Xiao
et al., 2003). From the effects of estradiol on stimu-
lated GABA release, we infer that the effect of estra-
diol on striatal DA activity may be mediated indi-
rectly through its effects on medium spiny GABAergic
neurons. Thus, through a decrease in inhibitory tone,
estradiol is hypothesized to enhance stimulated DA
release, by a release of presynaptic inhibition. In sup-
port of this idea, when baclofen (a GABAB receptor
agonist) is administered locally in the striatum,
extracellular concentrations of DA are decreased in
dialysate. Conversely, phaclofen (a GABAB receptor
antagonist) administered through the dialysis probe
to the striatum increased extracellular concentrations
of DA in dialysate (Smolders et al., 1995). These
results support the idea that GABAB receptors
directly regulate DA release in striatum.
In summary, we have shown that estradiol signifi-
cantly reduces Kþ-stimulated increases in GABA in
dialysate from female rat striatum. This finding of an
inhibition of stimulated GABA supports the hypothe-
sis that enhanced DA release evoked following estra-
diol treatment is mediated by GABAB receptors on
DA terminals. This finding provides new insights into
the mechanism(s) mediating the rapid effects of estra-
diol in the striatum, and is important for our under-
standing of how estradiol modulates neuronal activity
in the striatum.
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